Project Grant F31HL184832
- The National Heart, Lung, and Blood Institute awarded Texas A&M University System Health Science Center $758,499 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate a novel beta-adrenergic signaling mechanism that drives interleukin 17A (IL-17A) production and hypertension during chronic stress. The research examines how repeated social defeat stress exacerbates blood pressure rise induced by angiotensin II through IL-17A overproduction by...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 15, 2026, for Project Grant R03HL185264 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the mechanisms of CAV1.2 dysregulation in hypertension. CAV1.2, a voltage-activated calcium channel essential for blood pressure regulation, is abnormally active in spontaneously hypertensive rats and contributes to excessive...
- The National Heart, Lung, and Blood Institute awarded The University of Texas Southwestern Medical Center $246,000 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-specific differences in subclinical cardiovascular disease phenotypes and their relationship to psychosocial stress. The recipient will develop expertise in subclinical atherosclerosis measures and cardiovascular imaging phenotypes while examining whether chronic psychosocial...
- The National Heart, Lung, and Blood Institute awarded Wake Forest University Health Sciences $881,454 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish relationships between poor access to healthy food, inadequate clinical care, and hypertension progression in youth, and to identify strategies to overcome these barriers. The award supports research under the Study of the Epidemiology of Pediatric Hypertension (SUPERHERO) Registry, a longitudinal...
- The National Heart, Lung, and Blood Institute awarded Augusta University Research Institute, Inc. $707,903 on August 21, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the gut-immune-kidney axis in salt-sensitive hypertension and renal end-organ damage. The research addresses sex-specific mechanisms by which gut microbiota and their metabolites modulate immune responses contributing to salt-sensitive hypertension and kidney disease. The project will conduct...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of New Mexico Health Sciences Center a Project Grant of $586,637 (awarded September 1, 2025, with completion by August 31, 2027) under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research on immune dysfunction in hypoxic pulmonary hypertension. The research project will investigate the mechanisms by which chronic hypoxia causes immune dysregulation...
- The National Heart, Lung, and Blood Institute awarded $305,471 to ISA Associates, Inc. on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and pilot test a mobile stress management and medication adherence intervention targeting hypertension among men employed in manual and trade labor. The project addresses occupational stress as a driver of hypertension risk in construction, repair, production, and transportation workers, who experience...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute awarded the University of Oklahoma Health Sciences Center $638,245 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate hypothalamic melanocortin 4 receptor (MC4R) signaling pathways in sympathetic regulation of blood pressure, with particular focus on obesity-induced hypertension mechanisms. The research examines how MC4R signaling in hypothalamic neurons regulates sympathetic outflow and blood...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $874,014 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the relationship between gut microbiota, metabolite composition, and salt sensitivity of blood pressure. The research quantifies salt sensitivity of blood pressure as the change in 24-hour ambulatory mean arterial pressure from one week of high-salt to one week of low-salt diet in 50 adult subjects...
The National Heart, Lung, and Blood Institute awarded the University of South Carolina $100,228 on December 31, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on the mechanistic pathways linking hypertension, autoimmunity, and chronic psychological stress. The research tests whether chronic stress exacerbates immune system activation and hypertension in a female hypertensive mouse model of systemic lupus erythematosus (NZBWF1). The investigator's preliminary data demonstrate that subjecting healthy female mice to a 28-day chronic unpredictable stress protocol increases blood pressure and impairs renal mitochondrial function, and that female NZBWF1 mice with SLE develop hypertension associated with renal mitochondrial dysfunction and autoantibodies to mitochondrial antigens. The central hypothesis is that chronic stress will exacerbate renal mitochondrial dysfunction during SLE, leading to accelerated development of renal disease and hypertension. The work addresses a gap in understanding how chronic stress affects immune activation in patients with autoimmune disorders who have prevalent hypertension. Performance occurs at Columbia, South Carolina. The award period runs from December 31, 2026, through December 30, 2027. The assistance type is a project grant, a competitive research training award funding basic and translational research in cardiovascular disease prevention and treatment.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/15/26 | ||
| Not listed | $50.1k | 7/6/26 | ||
| Not listed | $50.1k | 7/6/26 |